Human Immunodeficiency Virus (HIV) Treatment Market Size, Share and Global Trend By Drug Class (Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), Protease Inhibitors (PIs), Integrase Inhibitor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) and Regional Forecast, 2024-2032

Human Immunodeficiency Virus (HIV) disease is a major global health issue. Human Immunodeficiency Virus (HIV) is a virus that leads to condition known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency Virus (HIV) attacks the body’s immune system specifically the CD4 cells (T cells), which help the immune system to fight against infections.

Absence of these CD4 cells, renders the body’s immune system inefficient to fight against chronic and acute diseases. Currently available treatment options are inefficient to completely cure the disease. Antiretroviral therapy (ART) is used as a treatment of Human Immunodeficiency Virus (HIV). Antiretroviral therapy (ART) slows down the progression of HIV in the body.

There is an increasing effort being undertaken by regional and national governments, and non-profit organizations, to promote awareness regarding Human Immunodeficiency Virus (HIV) disease, and to eradicate the social stigma associated with the disease. This is aimed towards increasing diagnosis rate of Human Immunodeficiency Virus (HIV) among patients in emerging countries.

These initiatives are anticipated to present a comparatively larger pool of people undergoing diagnosis for HIV, and subsequently fuel the demand for Human Immunodeficiency Virus (HIV) drugs during the forecast period. This along with increasing prevalence of Human Immunodeficiency Virus (HIV) disease in emerging countries including China, India, and African countries, are factors projected to drive the growth of the global human immunodeficiency virus (HIV) treatment market during 2019-2026.

According to World Health Organization (WHO) in 2017 estimated 36.9 million people were infected with Human Immunodeficiency Virus (HIV) globally, however only 21.7 million people received treatment. Major factors attributed to this were lack of diagnosed HIV patients, high cost of Human Immunodeficiency Virus (HIV) drugs & social stigma. These are some major factors restraining the growth of human immunodeficiency virus (HIV) treatment market.

Key Players Covered

Some of the major companies that are present in the global human immunodeficiency virus (HIV) treatment market are Abbott, Pfizer Inc., Novartis AG, Sanofi, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Gilead Sciences, Inc., ViiV Healthcare and other players.

SEGMENTATION

Key Insights

• Pipeline Analysis, Key Players / Region


• New Initiatives Undertaken by Government & Non-Government Organizations, Key Countries.


• Pricing Analysis, Key Players, 2018


• Key Mergers and Acquisitions.


• Prevalence of Human Immunodeficiency Virus (HIV) Disease, Key Countries.

Regional Analysis

The global human immunodeficiency virus (HIV) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominates the global human immunodeficiency virus (HIV) treatment market in 2018. In U.S, the Centers for Disease Control and Prevention sponsored a campaign that motivated people to get tested for HIV. This campaign resulted in increased number of diagnosed HIV patients and subsequently increased demand for treatment in U.S. In Middle East & Africa, human immunodeficiency virus (HIV) treatment market is projected to grow at a comparatively higher CAGR during 2019-2026. This region contains a large population of HIV patients in comparison with other regions. Undiagnosed HIV patients and low per capita healthcare expenditure are the major reasons restraining the growth of the market in this region. However, government initiatives to provide low-cost treatment in this region, is expected to drive the growth of the market during 2019-2026.

Key Industry Developments

• In 2018, researchers from Massachusetts Institute of Technology developed a capsule that was able to deliver a week worth of HIV drug in a single dose. This lead to increase in patient’s compliance for Antiretroviral Therapy.


• First in human (FIH) clinical trial was held by Zion Medical in 2018, which found that the synthetic peptide drug (Gammora) reduced the level of viral RNA in patients’ blood up to 90% after five weeks. When given in combination with the approved HIV drugs: lopinavir and ritonavir, it reduced viral RNA levels up to 99% after five weeks.


• In Aug 2018, Merck & Co., Inc. announced that FDA approved its two new antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of HIV-1, the most common strain of virus.


• In 2018 FDA approved Biktarvy, a daily single dose HIV medication by Gilead Sciences. Biktarvy is specifically indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace current antiretroviral regimen.


• In 2019, Food and Drug Administration finalized two guidelines on PrEP to support the manufacturers developing a new version of Antiretroviral medications.